These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34860333)

  • 21. XDR-
    Del Giacomo P; Raffaelli F; Losito AR; Fiori B; Tumbarello M
    Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203796
    [No Abstract]   [Full Text] [Related]  

  • 22. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Intravenous Colistin Monotherapy Versus Colistin Combined With Meropenem in Patients With Multidrug-Resistant Infections: A Retrospective Observational Study.
    Baig M; Rahim S; Naseem Khan R; Memon DD; Ansari ZA; Athar Khan M
    Cureus; 2023 Oct; 15(10):e47342. PubMed ID: 38022127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia.
    Khawcharoenporn T; Chuncharunee A; Maluangnon C; Taweesakulvashra T; Tiamsak P
    Int J Antimicrob Agents; 2018 Dec; 52(6):828-834. PubMed ID: 30236956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an
    Rico Caballero V; Almarzoky Abuhussain S; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS; Huband MD; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of Ceftolozane-Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections.
    Holger DJ; Rebold NS; Alosaimy S; Morrisette T; Lagnf A; Belza AC; Coyne AJK; El Ghali A; Veve MP; Rybak MJ
    Infect Dis Ther; 2022 Oct; 11(5):1965-1980. PubMed ID: 36048335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftolozane-tazobactam and Fosfomycin for rescue treatment of otogenous meningitis caused by XDR
    Frattari A; Savini V; Polilli E; Cibelli D; Talamazzi S; Bosco D; Consorte A; Fazii P; Parruti G
    IDCases; 2018; 14():e00451. PubMed ID: 30263888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant
    Chen J; Liang Q; Chen X; Wu J; Wu Y; Teng G; Huang M
    Infect Drug Resist; 2022; 15():655-667. PubMed ID: 35241917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymyxin Monotherapy vs. Combination Therapy for the Treatment of Multidrug-resistant Infections: A Systematic Review and Meta-analysis.
    Samal S; Samir SB; Patra SK; Rath A; Dash A; Nayak B; Mohanty D
    Indian J Crit Care Med; 2021 Feb; 25(2):199-206. PubMed ID: 33707900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
    Del Barrio-Tofiño E; López-Causapé C; Cabot G; Rivera A; Benito N; Segura C; Montero MM; Sorlí L; Tubau F; Gómez-Zorrilla S; Tormo N; Durá-Navarro R; Viedma E; Resino-Foz E; Fernández-Martínez M; González-Rico C; Alejo-Cancho I; Martínez JA; Labayru-Echverria C; Dueñas C; Ayestarán I; Zamorano L; Martinez-Martinez L; Horcajada JP; Oliver A
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.
    Escolà-Vergé L; Pigrau C; Los-Arcos I; Arévalo Á; Viñado B; Campany D; Larrosa N; Nuvials X; Ferrer R; Len O; Almirante B
    Infection; 2018 Aug; 46(4):461-468. PubMed ID: 29594953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of polymyxin B for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria in Thailand.
    Ngamprasertchai T; Boonyasiri A; Charoenpong L; Nimitvilai S; Lorchirachoonkul N; Wattanamongkonsil L; Thamlikitkul V
    Infect Drug Resist; 2018; 11():1219-1224. PubMed ID: 30154668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
    Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
    Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa.
    Rodríguez-Núñez O; Ripa M; Morata L; de la Calle C; Cardozo C; Fehér C; Pellicé M; Valcárcel A; Puerta-Alcalde P; Marco F; García-Vidal C; Del Río A; Soriano A; Martínez-Martínez JA
    J Glob Antimicrob Resist; 2018 Dec; 15():136-139. PubMed ID: 30036695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotic therapy and clinical outcomes of Pseudomonas aeruginosa (PA) bacteraemia.
    Tan SH; Teng CB; Ng TM; Lye DC
    Ann Acad Med Singap; 2014 Nov; 43(11):526-34. PubMed ID: 25523856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of Multidrug Resistant (MDR) and Extremely Drug Resistant (XDR) P. Aeruginosa Isolated from Patients in Tehran, Iran.
    Saderi H; Owlia P
    Iran J Pathol; 2015; 10(4):265-71. PubMed ID: 26351496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.